OncoMethylome Sciences Changes its Name to MDxHealth
(Thomson Reuters ONE) -
DURHAM, NC, and LIEGE, BELGIUM - October 6, 2010 - OncoMethylome Sciences SA
(Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) today announced that its
Extraordinary General Shareholders' Meeting passed the resolution on the
proposed name change of the company to MDxHealth SA. The name change was
unanimously supported by the shareholders present or represented at the meeting.
As announced on August 26 in the 2010 half-year results, MDxHealth is finalizing
a new strategy that focuses on high-value oncology based molecular diagnostic
testing for personalized medicine. The aim of this new strategy is to reap the
full benefits of the company's world-leading methylation platform by developing
DNA-biomarkers as stand-alone cancer diagnostics. The company has moved away
from its original model as a pure discovery company which out-licensed
biomarkers to third party developers and distributors. In the new strategy, the
company will end-develop products itself and sell them directly to treating
physicians and to pharmaceutical companies. This new strategy will enable the
company to control product development and sales rather than being entirely
dependent on partners.
To fully reflect the change in strategy and better position the company towards
patients, physicians and new pharmaceutical partners, management and the Board
of Directors proposed MDxHealth as the new name of the company. The name change
is particularly important for the company's direct sales to treating physicians
who want healthcare solutions. The company believes that "MDxHealth" captures
its new aspirations. "MDx", short for molecular diagnostics, has rapidly become
one of the key areas of healthcare innovation and progress; an area where
diagnostics and therapeutics converge. While "Health" is really what the
company's work is all about: assisting physicians to improve the life and health
of cancer patients. "MDxHealth" conveys the company's renewed mission: to
develop and commercialize advanced molecular diagnostic tests for personalized
cancer treatment.
As of October 7(th), the ticker symbol of the company listed on NYSE Euronext
Brussels and Amsterdam will become MDXH.
About MDxHealth
MDxHealth(TM) is a leading molecular diagnostics company that develops and
commercializes oncology based molecular diagnostic testing for personalized
medicine. The company's tests are based on proprietary gene methylation
technology and assist physicians and their patients with the accurate diagnosis
of cancer, prognosis of recurrence risk and prediction of response to a specific
therapy. MDxHealth collaborates with leading cancer research centers such as The
Johns Hopkins University, Duke University, Lovelace Respiratory Research
Institute, Eastern Virginia Medical School, Cleveland Clinic, Memorial Sloan
Kettering and major European medical centers. The company has a number of
commercial and collaborative partnerships with LabCorp, Merck/Schering-Plough,
GlaxoSmithKline Biologicals, Roche, Merck Serono, Qiagen and other industry
leaders.
For more information:
Dr. Jan Groen
CEO
+32 4.364.20.70 office
IR(at)mdxhealth.com
This press release contains forward-looking statements and estimates with
respect to the anticipated future performance of MDxHealth and the market in
which it operates. Such statements and estimates are based on assumptions and
assessments of known and unknown risks, uncertainties and other factors, which
were deemed reasonable but may not prove to be correct. Actual events are
difficult to predict, may depend upon factors that are beyond the Company's
control, and may turn out to be materially different. MDxHealth expressly
disclaims any obligation to update any such forward-looking statements in this
release to reflect any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any such statement is
based unless required by law or regulation.
[HUG#1449333]
2010-10-06 New name ENG:
http://hugin.info/137314/R/1449333/391270.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MdxHealth via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 06.10.2010 - 08:01 Uhr
Sprache: Deutsch
News-ID 44308
Anzahl Zeichen: 0
contact information:
Town:
Liège
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 200 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"OncoMethylome Sciences Changes its Name to MDxHealth"
steht unter der journalistisch-redaktionellen Verantwortung von
MdxHealth (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
